Compass Pathways Seeks Director for U.S. Site of Care to Advance Psilocybin Therapy for PTSD
Compass Pathways, a biotechnology company headquartered in London with a U.S. office in New Jersey, is actively developing COMP360 psilocybin, an investigational treatment for Post-traumatic Stress Disorder (PTSD) and treatment-resistant depression (TRD). COMP360 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for TRD. The company is currently executing a late-stage trial for COMP360 in PTSD and is seeking a Director, National Site of Care in the United States. This role is crucial for establishing strategic relationships with organized care groups, health systems, and treatment centers that will serve as early adopters of COMP360 therapy. The Director will lead a team responsible for site-of-care execution, ensuring consistent account planning, customer engagement, and launch readiness activities across the U.S. 
